Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal riskResearch in context

Authors: Gian Paolo Fadini, Enrico Longato, Mario Luca Morieri, Stefano Del Prato, Angelo Avogaro, Anna Solini, Mariella Baldassarre, Agostino Consoli, Sara Morganet, Antonella Zugaro, Marco Giorgio Baroni, Francesco Andreozzi, Adriano Gatti, Stefano De Riu, Andrea Del Buono, Raffaella Aldigeri, Riccardo Bonadonna, Alessandra Dei Cas, Angela Vazzana, Monica Antonini, Valentina Moretti, Patrizia Li Volsi, Miranda Cesare, Giorgio Zanette, Silvia Carletti, Paola D'Angelo, Gaetano Leto, Frida Leonetti, Luca D'Onofrio, Ernesto Maddaloni, Raffaella Buzzetti, Simona Frontoni, Giselle Cavallo, Susanna Morano, Tiziana Filardi, Umberto Capece, Andrea Giaccari, Antonio C. Bossi, Giancarla Meregalli, Fabrizio Querci, Alessia Gaglio, Veronica Resi, Emanuela Orsi, Stefano Fazion, Ivano G. Franzetti, Cesare Berra, Silvia Manfrini, Gabriella Garrapa, Giulio Lucarelli, Lara Riccialdelli, Elena Tortato, Marco Zavattaro, Gianluca Aimaretti, Franco Cavalot, Guglielmo Beccuti, Fabio Broglio, Bruno Fattor, Giuliana Cazzetta, Olga Lamacchia, Anna Rauseo, Salvatore De Cosmo, Rosella Cau, Mariangela Ghiani, Antonino Di Benedetto, Antonino Di Pino, Salvatore Piro, Francesco Purrello, Lucia Frittitta, Agostino Milluzzo, Giuseppina Russo

Source: The Lancet Regional Health. Europe, Vol 38, Iss , Pp 100847- (2024)

Subject Terms: Type 2 diabetes, Chronic kidney disease, SGLT2 inhibitors, Prevention, Observational, Public aspects of medicine, RA1-1270

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666776224000139; https://doaj.org/toc/2666-7762

Access URL: https://doaj.org/article/af262c8fdded4a0983a289dedffa98cc